Important Caveats About the Research Several important limitations should be acknowledged when reviewing the EpitalON literature: The majority of published studies originate from Khavinson's research group or closely affiliated laboratories Independent replication outside Russia has been limited, though the 2025 Biogerontology study represents a notable exception Human clinical data remains sparse, consisting mainly of small studies from one research group Most research has used injectable EpitalON, not oral formulations The peptide is not approved as a medicine in the UK, EU, or US How EpitalON Capsules Are Typically Taken Research Protocol Context The research literature commonly references cycles of 10-20 days at 5-10mg daily, repeated periodically (such as once or twice yearly)

Regarding the recommendation to clarify operational details of the five proposed collaborative elements, we appreciate this feedback and intend to provide additional resources to clarify details of CCAs in advance of the model start
Biological psychiatry, 43(7), 511519
Thus, it was likely that after tail amputation in rats, with/out heparin and warfarin administration, BPC 157 would counteract the consequences of administration of the NOS-blocker, L-NAME (i.e., prothrombotic effect and thereby thrombocytopenia) and/or NOS-substrate, L-arginine (i.e., antithrombotic effect and thereby more bleeding) [2931]